These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 9545668)

  • 41. [Susceptibilities of bacteria isolated from patients with respiratory infectious diseases to antibiotics (1992)].
    Ikemoto H; Watanabe K; Mori T; Igari J; Oguri T; Kobayashi K; Satou K; Matsumiya H; Saito A; Terai T; Tanno Y; Nishioka K; Arakawa M; Wada K; Okada M; Ozaki K; Aoki N; Kitamura N; Sekine O; Suzuki Y; Tanimoto H; Nakata K; Nakamori Y; Nakatani T; Kusano N
    Jpn J Antibiot; 1996 Jan; 49(1):34-70. PubMed ID: 8851305
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Bactericidal activity of arbekacin against methicillin-resistant Staphylococcus aureus. Comparison with that of vancomycin.
    Aoki Y
    Jpn J Antibiot; 1994 Jun; 47(6):640-6. PubMed ID: 8072172
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Susceptibilities of bacteria isolated from patients with respiratory infectious diseases to antibiotics (1994)].
    Ikemoto H; Watanabe K; Mori T; Igari J; Oguri T; Kobayashi K; Satou K; Matsumiya H; Saito A; Terai T; Tanno Y; Nishioka K; Arakawa M; Wada K; Okada M; Ozaki K; Aoki N; Kitamura N; Sekine O; Suzuki Y; Matsuda M; Tanimoto H; Nakata K; Nakamori Y; Kusano N
    Jpn J Antibiot; 1996 May; 49(5):419-55. PubMed ID: 8752860
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Antibacteriological activities of arbekacin and vancomycin against strains of MRSA].
    Ishii T; Takayama Y; Takase Y; Orikasa Y
    Jpn J Antibiot; 1994 Jun; 47(6):647-54. PubMed ID: 8072173
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Basic studies on combination effects of arbekacin and beta-lactam antibiotics on methicillin-resistant Staphylococcus aureus].
    Watanabe T; Sobu K; Takase Y; Kawabata T; Kanno M; Yoshida T
    Jpn J Antibiot; 1994 Jun; 47(6):701-9. PubMed ID: 8072178
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Yearly changes in antibacterial activities of cefozopran against various clinical isolates between 1996 and 2000--II. Gram-negative bacteria].
    Suzuki Y; Nishinari C; Endo H; Tamura C; Jinbo K; Hiramatsu N; Akiyama K; Koyama T
    Jpn J Antibiot; 2002 Apr; 55(2):154-80. PubMed ID: 12071094
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Yearly changes in antibacterial activities of cefozopran against various clinical isolates between 1996 and 2001--II. Gram-negative bacteria].
    Suzuki Y; Nishinari C; Endo H; Hiramatsu N; Akiyama K; Koyama T
    Jpn J Antibiot; 2003 Aug; 56(4):309-35. PubMed ID: 14567255
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [In vitro antibacterial activity of a new parenteral penem, sulopenem].
    Yoshida T; Tateda E; Hiramatsu K; Yokota T
    Jpn J Antibiot; 1996 Apr; 49(4):324-37. PubMed ID: 8786624
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Combined effect of sulbactam/cefoperazone and other antibiotics against clinical isolates of multi-resistant strains. II. In vitro combined effects of sulbactam/cefoperazone with imipenem/cilastatin, cefuzonam, flomoxef, amikacin or tobramycin].
    Kouda M; Kumagai I; Kobayashi J; Sugai R; Matsuzaki H
    Jpn J Antibiot; 1991 Feb; 44(2):130-9. PubMed ID: 2041154
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Susceptibilities of bacteria isolated from patients with lower respiratory infectious diseases to antibiotics (2003)].
    Goto H; Takeda H; Kawai S; Nakadate T; Shimada K; Nakano K; Suwabe A; Yokouchi H; Okada S; Ashino Y; Ikemoto H; Gejyo F; Igari J; Okada M; Oguri T; Aoki N; Mori T; Yamamoto M; Kitamura N; Inoue H; Suzuki Y; Karasawa Y; Tosaka M; Kudo K; Kobayashi N; Kohno S; Tanaka T; Hirakata Y; Kondo A; Matsuda J; Nakano M; Sumitomo M; Nasu M; Niki Y; Hiramatsu K; Suga M; Suzuki Y
    Jpn J Antibiot; 2005 Jun; 58(3):326-58. PubMed ID: 16161758
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (2000). I. Susceptibility distribution].
    Kumamoto Y; Tsukamoto T; Fujime M; Fujita K; Hirose T; Matsukawa M; Takahashi S; Kunishima Y; Igari J; Ogihara M; Ishibashi K; Oguri T; Shigeta S; Yamaguchi K; Matsumoto T; Kashitani F; Yoshida H; Imafuku Y; Murai M; Ooe H; Nishikawa M; Watanabe K; Kobayashi Y; Uchida H; Oka T; Kitamura M; Takano Y; Matsuoka Y; Matsuda S; Sato S; Furuhama T; Kumon H; Monden K; Aoki S; Mochida C; Hirakata Y; Kohno S; Miyazaki Y; Tomono K
    Jpn J Antibiot; 2002 Aug; 55(4):370-98. PubMed ID: 12378869
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Treatment with arbekacin of surgical infections by resistant strains of Staphylococcus aureus. Arbekacin Study Group].
    Morimoto K; Nakatani S; Kaji M; Kinoshita H; Fujimoto M; Hirata S; Ueda T; Tamate S; Yamazaki O
    Jpn J Antibiot; 1994 Jun; 47(6):826-36. PubMed ID: 8072193
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Antibacterial activities of arbekacin against recently isolated methicillin-resistant Staphylococcus aureus (I)].
    Deguchi K; Yokota N; Koguchi M; Suzuki Y; Suzuki K; Fukayama S; Ishihara R
    Jpn J Antibiot; 1993 Mar; 46(3):234-41. PubMed ID: 8510320
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Susceptibilities of bacteria isolated from patients with lower respiratory infectious diseases to antibiotics (2000)].
    Shimada K; Terai T; Igari J; Inoue H; Nakadate T; Oguri T; Suwabe A; Obata R; Ikemoto H; Ohno I; Okada S; Hayashi K; Mori T; Nakano K; Arakawa M; Gejyo F; Igarashi K; Yokouchi H; Okada M; Ito A; Sumitomo M; Aoki N; Matsushima T; Niki Y; Kitamura N; Suga M; Suzuki Y; Karasawa Y; Tosaka M; Nakata K; Nakatani T; Kohno S; Tomono K; Miyazaki Y; Inagawa H; Hirakata Y; Aoki S; Matsuda J; Kudo K; Kobayashi N; Kinoshita T; Konosaki H; Nasu M; Nagai H; Kobayashi H; Kawai S; Takayasu S; Hiramatsu K; Nakano T
    Jpn J Antibiot; 2002 Oct; 55(5):537-67. PubMed ID: 12532637
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Evaluation of bactericidal activity of arbekacin in mixed culture with MRSA and Pseudomonas aeruginosa using an in vitro pharmacokinetic simulation system].
    Tsuji A; Sugano T; Yamaguchi K; Goto S; Takada T; Takase Y; Yoshida T
    Jpn J Antibiot; 1994 Jun; 47(6):655-63. PubMed ID: 8072174
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Antibiotic efficacies of combined uses of arbekacin and various antibiotics against methicillin-resistant Staphylococcus aureus].
    Deguchi K; Yokota N; Koguchi M; Suzuki Y; Suzuki K; Fukayama S; Ishihara R; Oda S
    Jpn J Antibiot; 1994 Jun; 47(6):693-700. PubMed ID: 8072177
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Susceptibilities of bacteria isolated from patients with lower respiratory infectious diseases to antibiotics (1999)].
    Shimada K; Nakano K; Ohno I; Okada S; Hayashi K; Yokouchi H; Arakawa M; Gejyo F; Igarashi K; Ikemoto H; Mori T; Okada M; Ozaki K; Igari J; Aoki N; Oguri T; Kitamura N; Terai T; Suzuki Y; Inoue H; Nakadate T; Karasawa Y; Ito C; Yoshida T; Nakata K; Nakatani T; Inagawa H; Ando M; Suga M; Sato K; Kudo K; Kobayashi N; Tosaka M; Hasegawa M; Kohno S; Tomono K; Miyazaki Y; Kobayashi H; Kawai S; Takayasu S; Hirakata Y; Matsuda J; Mochida C; Ito A; Sumitomo M; Nasu M; Nagai H; Matsushima T; Niki Y; Hiramatsu K; Nakano T
    Jpn J Antibiot; 2001 Jul; 54(7):331-64. PubMed ID: 11560054
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Antimicrobial activities of cefozopran against Streptococcus pneumoniae from children].
    Deguchi K; Koguchi M; Suzuki Y; Tanaka S; Ishihara R; Fukayama S; Oda S
    Jpn J Antibiot; 1996 Jul; 49(7):703-9. PubMed ID: 8828071
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Bacteriological evaluation of combined effects of vancomycin and beta-lactams. II. Results against gram-negative rods].
    Deguchi K; Yokota N; Koguchi M; Suzuki Y; Fukayama S; Ishihara R; Oda S
    Jpn J Antibiot; 1993 Nov; 46(11):946-52. PubMed ID: 8309070
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Bacteriological and clinical break points: evaluation of the usefulness of cefozopran based on MIC].
    Ishigo S; Iriyama J; Asano Y; Minakuchi K
    Jpn J Antibiot; 1999 May; 52(5):439-47. PubMed ID: 10480051
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.